Brought to you by 
BI receives options on Crystal Bioscience’s chicken-produced antibodies
27 Feb 2014
Executive Summary
Crystal Bioscience Inc. (chicken monoclonal antibodies) agreed to discover antibodies against multiple targets chosen by Boehringer Ingelheim GMBH. The Big Pharma has options to license development and commercialization rights to resulting therapeutics. The partners have previously worked together.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Transgenics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BI receives options on Crystal Bioscience’s chicken-produced antibodies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice